European Heart Journal-Cardiovascular Pharmacotherapy

Article	Citations
Comments on—The noradrenaline dosing in the new 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure	72
Effects of renin–angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomized controlled trials	68
Associations of omega-3 fatty acids vs. fenofibrate with adverse cardiovascular outcomes in people with metabolic syndrome: propensity matched cohort study	60
Early initiation of SGLT2 inhibitors after acute myocardial infarction	58
Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: Scandinavian cohort study	49
Sex-related differences in cardiovascular pharmacotherapy: fiction or fact? Why can’t we see the evidence?	41
The search for the holy grail: the balance between the risk of thrombosis and bleeding in patients	36
Interdisciplinary recommendations for recurrent hyperkalaemia: insights from the GUARDIAN-HK European Steering Committee	36
Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cotransporter 2 inhibitors in patients with atherosclerotic cardiovascular disease and heart failure: a cohor	34
Anticoagulation for the prevention of arterial thromboembolism in cancer patients by primary tumour site: a systematic review and meta-analysis of randomized trials	34
Current evidence and future perspective for the management of left-sided prosthetic valve thrombosis	33
Edoxaban for 12 vs. 3 months in cancer-associated isolated distal deep vein thrombosis according to different doses: insights from the ONCO DVT study	31
Net clinical benefit of extended dual pathway inhibition according to baseline risk in patients with chronic coronary syndrome: a COMPASS substudy	30
Treatment with dual antiplatelet therapy after an acute coronary event may often be tailor-made for the patient	29
Need for more evidence of safety in the pharmacological therapy of anaemia in chronic kidney disease: a cardiovascular perspective	28
Editorial on incidence and outcomes of transient new onset atrial fibrillation complicating acute coronary syndromes: results from a systematic review and meta-analysis	28
Flecainide to prevent atrial arrhythmia after patent foramen ovale closure, Rationale and design of the randomized AFLOAT study	27
Impact of transfusion strategy on platelet aggregation and biomarkers in myocardial infarction patients with anemia	27
Efficacy and safety of P2Y12 inhibitor monotherapy after complex PCI: a collaborative systematic review and meta-analysis	26
Inhibition of interleukin-1 or -6 after myocardial infarction: pros, cons, and future perspectives	26
Management of patients with congenital bleeding disorders and cardiac indications for antithrombotic therapy	25
Subcutaneous furosemide patch: heart failure decongestion ‘from the comfort of your home’	25
All about clinical trials	23
Cardiac adverse drug reactions to COVID-19 vaccines. A cross-sectional study based on the Europe-wide data	22
Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy	21

Anti-inflammatory pharmacotherapy in patients with cardiovascular disease	21
New ways of mitigating aldosterone in cardiorenal disease	21
Long-term effects of phosphodiesterase-5 inhibitors on cardiovascular outcomes and death: a systematic review and meta-analysis	19
Safety and efficacy of early initiation of sodium-glucose cotransporter-2 inhibitors after an acute coronary syndrome event: a meta-analysis of randomized controlled trials	19
Association of guideline-directed medical therapy adherence with outcomes after fractional flow reserve-based deferral of revascularization	19
De-escalation versus shortening of dual antiplatelet therapy	19
Antithrombotic therapy and cardiovascular outcomes after transcatheter aortic valve implantation in patients without indications for chronic oral anticoagulation: a systematic review and network meta-	19
Impact of left ventricular ejection fraction on the effect of beta-blocker therapy on 1-year mortality in acute coronary syndrome patients	18
Effectiveness and safety of rivaroxaban vs. apixaban in patients with atrial fibrillation and peripheral artery disease	18
Late breaking clinical trials at ACC 22	18
Cardiovascular prevention and risk factors	18
Long-term antiplatelet monotherapy after PCI: searching for the smart choice	18
Authors’ reply to: “Preventing Atrial Fibrillation with SGLT2 Inhibitors: Time, Sex, and Substrate” by Karakasis et al	18
News in cardiovascular pharmacotherapy from the ACC.24 Meeting	16
Pharmacotherapy of patients with heart failure and atrial fibrillation: let's get the evidence!	16
Focus on different lipid-lowering treatment and genetic testing for optimal pharmacotherapy use in the clinic	16
Stroke risk stratifications according to CHA2DS2-VASc vs. CHA2DS2-VA in patients with atrial fibrillation: insights from the GLORIA-AF registry	15
Adenosine as adjunctive therapy in acute coronary syndrome: a meta-analysis of randomized controlled trials	15
Photoinduced skin reactions of cardiovascular drugs—a systematic review	15
Correction to: Aspirin-free strategy for percutaneous coronary intervention in acute coronary syndrome based on the subtypes of acute coronary syndrome and high bleeding risk: the STOPDAPT-3 trial	15
The dual endothelin-1 antagonist aprocitentan alleviates mitochondrial oxidative stress in human cardiac fibroblasts	15
Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: apost hocanalysis of the ATHENA trial	15
Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis	14
Apixaban outcomes in atrial fibrillation patients with a single-dose reduction criterion: ASPIRE 1-year results	14
Entering a new era of antiplatelet therapy: the 4D-ACS trial	14
Are NOACs always the best strategy in elderly AF patients?	14
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023	14
Chronic coronary syndrome and new-onset atrial fibrillation or venous thromboembolism: how best to manage antithrombotic therapy strategies	14
Focus on different aspects of atrial fibrillation	13
Effects of renin–angiotensin system inhibitor type and dosage on survival after transcatheter aortic valve implantation	13
What's new in pharmacotherapy at ESC Congress 2023?	13
Efficacy of new medical therapies in patients with heart failure, reduced ejection fraction, and chronic kidney disease already receiving neurohormonal inhibitors: a network meta-analysis	13
Initial statin dose after myocardial infarction and long-term cardiovascular outcomes	13
Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry	13
Seeking for the Boundaries of De-escalation in Antiplatelet Therapy for Acute Coronary Syndromes	12
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022	12
Association of PCSK9 inhibitors with mortality: insights from a retrospective cohort analysis	12
Cardiovascular outcomes in hepatitis C virus infected patients treated with direct acting antiviral therapy: a retrospective multi-institutional study	12
Effectiveness and safety of direct oral anticoagulation vs. warfarin in frail patients with atrial fibrillation	12
Immunomodulatory effect of different statin regimens on regulatory T-cells in patients with acute coronary syndrome: a systematic review and network meta-analysis of randomized clinical trials	11
Inotropes and mortality in patients with cardiogenic shock: an instrumental variable analysis from the SWEDEHEART registry	11
Who requires longer-term anticoagulation therapy for venous thromboembolism from the perspective of precision medicine?	11
An Old Drug in a New Era: Digitoxin in the Spotlight After DIGIT-HF	11
Cardiovascular disease and cardiovascular pharmacotherapy: the challenges and the research continue	11
Is the TIME study on antihypertensive therapy and chronotropic effects on cardiovascular outcomes a pragmatic trial?	11
Diuretic strategies in acute heart failure: a systematic review and network meta-analysis of randomized clinical trials	11
Extensive LDL-cholesterol lowering by PCSK9 inhibitor on the risk of venous thrombosis	11
Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled tr	10
FLOW trial stopped early due to evidence of renal protection with semaglutide	10
Does LDL-C determination method affect statin prescribing for primary prevention? A register-based study in Southern Denmark	10

Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy	10
Impact of body mass on P2Y12-inhibitor de-escalation in acute coronary syndromes—a substudy of the TROPICAL-ACS trial	10
Use of proton pump inhibitors is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nested case-control study	10
New-onset syncope in diabetic patients treated with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: a Chinese population-based cohort study	10
An aspirin-free strategy for percutaneous coronary intervention in patients with diabetes: a pre-specified subgroup analysis of the STOPDAPT-3 trial	10
Sodium–glucose cotransporter 2 inhibitor use in early-phase acute coronary syndrome with severe heart failure	10
RNA-targeted therapeutics in cardiovascular disease: the time is now	9
Treating patients with anticoagulants and antiplatelet drugs is always a balance between risk for thrombosis vs. risk for bleeding	9
Effect of SGLT2i on kidney outcomes of individuals with type 2 diabetes according to body mass index: nationwide cohort study	9
Use of methylphenidate is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nationwide nested case-control study	9
Corrigendum to: Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharm	9
Response to—Current evidence and future perspective for the management of left sided prosthetic valve thrombosis	9
We have much more to learn about sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists	9
Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease	9
The role of inotropes in cardiogenic shock: to help, to harm or do nothing at all?	8
Fenofibrate therapy and risk of heart failure outcomes in patients with Type 2 diabetes: a propensity-matched cohort study	8
Cardiovascular risks of continuing vs. initiating NSAIDs after first-time myocardial infarction or heart failure: a nationwide cohort study	8
Corrigendum to: Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: A nationwide registry analysis	8
Tolerability and efficacy of sodium-glucose co-transporter 2 inhibitors in patients with cardiac amyloidosis: a meta-analysis of observational studies	8
The ESC Working Group on cardiovascular pharmacotherapy: continuity through transformation	8
2024 ESC Guidelines for the management of elevated blood pressure and hypertension: what is new in pharmacotherapy?	8
News in cardiovascular pharmacotherapy from the ACC.25 Meeting	8
Future of antithrombotic therapy for heart failure with coronary artery disease	7
Special focus on the new anti-diabetic drugs	7
Ranolazine in patients with chronic coronary syndromes: real-world data provide new evidence on the antiarrhythmic properties of the drug	7
Aspirin vs. clopidogrel monotherapy beyond 1 month after complex percutaneous coronary intervention: a pre-specified subgroup analysis of the STOPDAPT-3 trial	7
Novel therapeutic targets and emerging treatments for atherosclerotic cardiovascular disease	7
Platelet inhibition with orodispersible ticagrelor in acute coronary syndromes according to morphine use: the TASTER study final results	7
Beta blockers and long-term outcome after coronary artery bypass grafting: a nationwide observational study	7
Triglycerides revisited: is hypertriglyceridaemia a necessary therapeutic target in cardiovascular disease?	7
Combination therapy with moderate-intensity atorvastatin and ezetimibe vs. high-intensity atorvastatin monotherapy in patients treated with percutaneous coronary intervention in practice: assessing RA	7
Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT	6
Lipid treatment	6
GLP-1 receptor agonists: new game changing drugs in patients with heart failure with preserved ejection fraction and obesity	6
Cost-effectiveness of clopidogrel vs. ticagrelor in patients of 70 years or older with non-ST-elevation acute coronary syndrome	6
Atrial fibrillation has gone from a boring disease to a very hot condition. Why is that?	6
Effects of beta-blockers on quality of life and well-being in patients with myocardial infarction and preserved left ventricular function—a prespecified substudy from REDUCE-AMI	6
Antiplatelet treatment, dyslipidemia, cardiac side events during COVID-19 vaccine, antithrombotic treatment with different BMI	6
A systematic review and meta-analyses on the effects of atorvastatin on blood pressure and heart rate	6
Correction to: New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024	6
Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease	6
Management of dyslipidaemia in patients with comorbidities: facing the challenge	6
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation	6
Updated meta-analysis of randomized controlled trials on the safety and efficacy of different prophylactic anticoagulation dosing regimens in non-critically ill hospitalized patients with COVID-19	6
SGLT2 inhibitors and cardiovascular outcomes in patients with acute myocardial infarction: a retrospective cohort analysis	6
ESC/EAS guidelines for the detection, prevention, and treatment of individuals at risk of a first myocardial infarction: effect of 5 years of updates and the new SCORE2	6
Cholinesterase inhibitors and reduced risk of hospitalization and mortality in patients with Alzheimer's dementia and heart failure	5
The search for the perfect antiplatelet treatment continues	5
Acute effects of empagliflozin on left atrial and ventricular filling parameters using echocardiography—a subanalysis of the EMPAG-HF trial	5
Initiation of eplerenone or spironolactone, treatment adherence, and associated outcomes in patients with new-onset heart failure with reduced ejection fraction: a nationwide cohort study	5
Corrigendum to: Digoxin use in contemporary heart failure with reduced ejection fraction: An analysis from the Swedish Heart Failure Registry	5
Early DAPT Discontinuation After Acute Myocardial Infarction: Finding the Optimal TARGET	5
A gene risk score using missense variants in SLCO1B1 is associated with earlier onset statin intolerance	5
Pharmacogenetic testing to broaden patient eligibility for mavacamten	5
2024 ESC guidelines on chronic coronary syndromes: what is new in pharmacotherapy?	5
New data on NOVEL ORAL ANTICOAGULANT, SGLT2i, lipid treatment and genetics	5
The role of cangrelor in acute and high-risk PCI settings	5
Corrigendum to: The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy	5
LDL lowering effect of PCSK9 inhibition is reduced in women	5
Our knowledge about atrial fibrillation steadily increases	5
Hypokalaemia in patients with type 2 diabetes and chronic kidney disease: the effect of finerenone—a FIDELITY analysis	5
SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis	4
2023 ESC Guidelines on ACS: what is new in antithrombotic therapy?	4
Non-steroidal anti-inflammatory drugs and risk of myocardial infarction adjusting for use of proton pump-inhibitors in patients with no major risk factors: a nested case-control study in the UK Clinic	4
Association between sacubitril/valsartan and risk of dementia in patients with heart failure: a nationwide cohort study	4
Heart failure pharmacological treatments and outcomes in heart failure with mildly reduced ejection fraction	4
Corrigendum to: Treatment of Fabry Disease management with migalastat—outcome from a prospective 24 months observational multicenter study (FAMOUS)	4
Emerging antihypertensive therapies and cardiovascular, kidney, and metabolic outcomes: a Mendelian randomization study	4
Lipid-lowering therapies for aortic stenosis: a drug-target Mendelian randomization study	4
Letter to the editor: 1-year clinical outcomes of bivalirudin vs. unfractionated heparin in patients with type 2 diabetes undergoing elective percutaneous coronary intervention	4
EHJCVP Reviewers 2022	4
Antiplatelet effect, safety, and pharmacokinetics of vicagrel in patients with coronary artery disease undergoing percutaneous coronary intervention	4
Beta-adrenergic blockade increases pulmonary vascular resistance and causes exaggerated hypoxic pulmonary vasoconstriction at high altitude: a physiological study	4
Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry	4
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024	4
Comparison of low-density lipoprotein cholesterol equations in patients with dyslipidaemia receiving cholesterol ester transfer protein inhibition	4
The impact of sodium–glucose cotransporter 2 inhibitors in post-myocardial infarction management: insights from EMPACT-MI and DAPA-MI trials	4
CLEAR results, cloudy impact: colchicine's neutral role in ST-segment elevation myocardial infarction	4
Cardiovascular events in patients treated with bempedoic acid vs. placebo: systematic review and meta-analysis	4
2022 ESC Guidelines on cardio-oncology: how can we improve the cardiovascular health of patients with cancer and cancer survivors?	4

Characteristics and outcomes in patients with a prior myocardial infarction treated with extended dual antiplatelet therapy with ticagrelor 60 mg: findings from ALETHEIA, a multi-country observational	3
Sex-related differences in platelet aggregation	3
Fibrates: one more lost paradise in lipid treatment	3
Hypertension in pregnancy—what's new in the 2023 ESH Guidelines for the management of arterial hypertension	3
Optimizing individual heart failure treatment	3
GPVI inhibition: Advancing antithrombotic therapy in cardiovascular disease	3
Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48	3
Antithrombotic therapy in patients after transcatheter aortic valve implantation: a network meta-analysis	3
The effect of discontinuing beta-blockers after different treatment durations following acute myocardial infarction in optimally treated, stable patients without heart failure: a Danish, nationwide co	3
Reduction of hypokalaemia with finerenone: a drug or class-specific effect?	3
Anticoagulation in cancer-associated thrombosis: how long should the therapy be?	3
Subcutaneous furosemide in heart failure: a systematic review	3
Lipid-lowering and antihypertensive drugs on aortic disease risk: insights from Mendelian randomization analysis and real-world pharmacovigilance data	3
Postoperative atrial fibrillation and stroke after non-cardiac surgery: a systematic review and meta-analysis	3
Post-diagnostic statin use and its association with cancer recurrence and mortality in breast cancer patients: a systematic review and meta-analysis	3
Reply to ‘Cholinesterase inhibitors are associated with reduced mortality in patients with Alzheimer's disease and previous myocardial infarction’	3
Sodium glucose co-transporter 2 inhibitors and quality of life in patients with heart failure: a comprehensive systematic review and meta-analysis of randomized controlled trials	3
Dapagliflozin in patients with myocardial infarction without diabetes or prior heart failure	3
Antidiabetic drugs and hypoglycaemia risk in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants	3
Valve thrombosis and antithrombotic therapy after bioprosthetic mitral valve replacement: a systematic review and meta-analysis	3
Balancing the risks of bleeding and ischaemia in myocardial infarction patients at high bleeding risk	3
What is optimal dual anti-platelet therapy duration after percutaneous coronary intervention?	3
Bleeding and thrombosis	3
Reaping the rewards of a simplified dosing regimen	3
Head-to-head efficacy and safety of rivaroxaban, apixaban, and dabigatran in an observational nationwide targeted trial	3
Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD	3
Use of sodium-glucose cotransporter-2 inhibitors and the risk for sudden cardiac arrest and for all-cause death in patients with type 2 diabetes mellitus	3
Validation of a novel direct method to determine reduced adherence to atorvastatin therapy	3
Phosphodiesterase 5 and its inhibitors with ischaemic heart disease: a Mendelian randomization analysis and a real-world study	2
Bioinformatic platforms for clinical stratification of natural history of atherosclerotic cardiovascular diseases	2
Oral anticoagulants and antiplatelet treatment in different settings	2
Racial and ethnic differences in pharmacotherapy to prevent coronary artery disease and thrombotic events	2
Extended, standard, or De-escalation antiplatelet therapy for patients with coronary artery disease undergoing percutaneous coronary intervention? A trial-sequential, bivariate, influential, and netwo	2
P2Y12 inhibition in high bleeding risk patients: making the right decision in a complex setting	2
After 30 years, the first endothelin-receptor antagonist (Aprocitentan) is approved for the treatment of arterial hypertension	2
Long-term effectiveness of ACE inhibitors or angiotensin receptor blockers in myocardial infarction with preserved left ventricular ejection fraction	2
Pre-treatment with P2Y12 inhibitors in acute myocardial infarction with cardiogenic shock	2
Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi after myocardial infarction: reply	2
Prevention of atrial fibrillation with SGLT2 inhibitors across the spectrum of cardiovascular disorders: a meta-analysis of randomized controlled trials	2
Correction to: Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials	2
Repurposing low-dose naltrexone for the prevention and treatment of immunothrombosis in COVID-19	2
Low-dose aspirin and incident atrial fibrillation in healthy older individuals: a post-hoc analysis of the ASPREE trial	2
Management of dyslipidaemia in patients with comorbidities—facing the challenge: type 1 diabetes mellitus	2
To treat or not to treat	2
Effects of sodium-glucose co-transporter 2 inhibitors on heart failure events in chronic kidney disease: a systematic review and meta-analysis	2
Intensive blood pressure control in patients with a history of heart failure: the Systolic Blood Pressure Intervention Trial (SPRINT)	2
Antithrombotic treatment beyond 1 year after percutaneous coronary intervention in patients with atrial fibrillation	2
Identification of anticancer drugs associated to cancer therapy-related cardiac dysfunction: a VigiBase® disproportionality analysis	2
The Danish-Norwegian randomized trial on beta-blocker therapy after myocardial infarction: Design, rationale, and baseline characteristics	2
Interleukin-1 blockade with anakinra and heart failure following ST-segment elevation myocardial infarction: results from a pooled analysis of the VCUART clinical trials	2
Potential bias in observational PCSK9 inhibitor study	2
Unexplored horizons on sex bias and progression of heart failure with preserved ejection fraction	2
The revolution in pharmacotherapy: from herbs to pills, moulds, antibodies to genetic tools	2
Sex-related variations in platelet reactivity in presence or absence of antiplatelet therapy	2
Clinical features modifying the cardiovascular benefits of GLP-1 receptor agonists: a systematic review and meta-analysis	2
First-in-human trial of PCSK9 gene editing therapy for lowering cholesterol: a new frontier in cardiovascular pharmacotherapy? News from AHA	2